EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Curriculum Vitae

Personal information

Aurora Signorazzi

Work experience

Quality Assessor at Medicine Evaluation Board (Utrecht, the Netherlands)

Sep 2024 - present

Assessment of the quality module of Common Technical Documents for biotechnological medicines.

Quality Control Scientist/Project Leader at Janssen Biologics (Leiden, NL)

Jul 2023 - Aug 2024

- Technical specialist and investigation lead for molecular and cell-based safety release tests of J&J commercial products; global point of contact for J&J virological center of excellence.
- Project leader for development and validation of high-throughput GMP-grade methods (NGS, dPCR); planning, financial budgeting, presentations at scientific conferences.

Project Manager at Leiden University Medical Center (Leiden, NL)

Feb - Jun 2023

Coordination of research activities for international consortia and with commercial parties; management of progress, logistics, resources and budget.

Research and Development Scientist at Janssen Vaccines and Prevention (Leiden, NL)

Oct 2020 - Jan 2023

- Subject matter expert for molecular, cell-based and in vivo release tests. Global support for transfers and investigations; authorship of SOPs, study reports and regulatory dossiers' safety granules.
- Project leader for assessment and development of innovative materials (mAbs for replacement of serum) and methods (NGS and ddPCR for replacement of in vivo and in vitro assays).
- Management of contract research organizations and stakeholders in cross-functional development teams. Supervision of associate scientists and planning of lab activities.

Education and training

PhD in Virology and Immunology at University of Groningen (NL)

Aug 2016 - Sep 2020

MSc in Cellular and Molecular Biology at University of Rome "Tor Vergata" (IT)

Oct 2013 - Oct 2016

BSc in Biotechnology at University of Rome "Tor Vergata" (IT)

Sep 2010 - Oct 2013

Additional information

Publications

- **In Vitro Characterization of the Innate Immune Pathways Engaged by Live and Inactivated Tick-Borne Encephalitis Virus**
  A Signorazzi, JLA Pennings, MP Etna, M Noya, EM Coccia, A Huckriede
  Vaccines 9 (6), 664, 2021
- **In vitro approaches for the evaluation of human vaccines**
  A Signorazzi
  University of Groningen, 2021
- **Human plasmacytoid dendritic cells at the crossroad of type I interferon-regulated B cell differentiation and antiviral response to tick- borne encephalitis virus**
  MP Etna, A Signorazzi, D Ricci, M Severa, F Rizzo, E Giacomini, A Gaggioli, I Bekeredjian-Ding, A Huckriede, EM Coccia
  PLoS Pathogens 17 (4), e1009505, 2021
- **In vitro assessment of tick-borne encephalitis vaccine: suitable human cell platforms and potential biomarkers**
  A Signorazzi, MP Etna, EM Coccia, A Huckriede
  ALTEX: Alternatives to Animal Experimentation 38 (3), 431-441, 2021
- **Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production**
  J Herrera-Rodriguez, A Signorazzi, M Holtrop, J de Vries-Idema, A Huckriede
  Vaccine 37 (12), 1630-1637, 2019

Projects

Memberships

Other Relevant Information